Clinical Trial Update: Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842) [Phase 3]

View source ↗

Summary

A Phase 3 double-blind trial evaluating sitagliptin added to ipragliflozin in Japanese adults with type 2 diabetes and inadequate glycemic control.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin (sitagliptin)
• ipragliflozin (ipragliflozin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2018-03-07